Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar

Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar

Source: 
Pharmaforum
snippet: 

Novartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar of Biogen’s multiple sclerosis drug Tysabri (natalizumab).